Skip to content

Supraclavicular Brachial Plexus Block Using Ropivacaine Alone and With Dexmedetomidine

Supraclavicular Brachial Plexus Block Using Ropivacaine Alone or Combined With Dexmedetomidine for Upper Limb Surgery: A Prospective, Randomized, Double-blinded, Comparative Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02393677
Enrollment
80
Registered
2015-03-19
Start date
2011-07-31
Completion date
2012-07-31
Last updated
2015-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brachial Plexus Anesthesia

Brief summary

80 American Society of Anesthesiologists (ASA) grade I-II patients, 18-60 years old,scheduled for elective upper limb orthopaedic surgery under supraclavicular brachial plexus block, were included in this prospective study. The patients were randomly assigned to group R (Ropivacaine alone) and group RD (Ropivacaine and dexmedetomidine) (40 patients in each group). Group R received Ropivacaine 0.50% (30 cc) + placebo and group RD received Ropivacaine 0.50% (30 cc) + dexmedetomidine 1 µg/kg.

Detailed description

After Institutional Ethical Committee approval and written informed consent, a prospective, randomized, double-blinded study was carried out on 80 ASA Grade I and II patients of either sex, aged 18-60 years, undergoing various orthopaedic surgeries on the upper limb under supraclavicular brachial plexus block. A power analysis was performed to determine the necessary number of patients for each group based on duration of analgesia. With a 2-sided type I error of 5% and study power at 80%, it was estimated that 38 patients would be needed in each group in order to detect a difference of 35 min in the duration of analgesia between the 2 groups. The study was conducted in two groups of 40 patients each. Patients were randomly chosen by computer-generated random selection to one of the following groups: Group R: Ropivacaine 0.50% (30 cc) + Placebo Group RD: Ropivacaine 0.50% (30 cc) + Dexmedetomidine 1 µg/kg Randomization was performed by an independent statistician and concealed from patients and investigators until completion of statistical analysis. Patients were instructed preoperatively about use of the verbal rating scale (VRS) for pain assessment (VRS: 0 = no pain, 10=worst pain possible). On arrival in the operation room, baseline heart rate, blood pressure and oxygen saturation were recorded. An intravenous line was secured in the unaffected limb and Ringer's lactate was started. Patients were given midazolam intravenous (IV) (0.03 mg/kg) as premedication 10-15 min before beginning each blocks technique. Subcutaneous injection with 2 mL of 2% lidocaine was administered at the needle insertion site. All the patients received brachial plexus block through the supraclavicular approach by an experienced anesthesiologist different from the one assessing the patient intra- and post-operatively. Both were blinded to the treatment groups. Neural localization was achieved by using a nerve locator (Stimuplex® Dig RC, B.Braun, Melsungen AG, Melsungen, Germany) connected to a 22 G, 50-mm-long stimulating needle (Stimuplex, Braun, Germany). The location end point was a distal motor response with an output lower than 0.5 milliampere (mA). Following negative aspiration, 30 mL of a solution containing local anesthetic combined with placebo or dexmedetomidine as mentioned above was injected and the use of Dexmedetomidine was off-label. A 5-min compression was performed to facilitate an even drug distribution. Sensory blockade was assessed every 3 min and motor block was evaluated every 5 min within the first 30 min following completion of drug administration. Sensory block was confirmed by pinprick sensation using a 23-G needle in all dermatomes of the brachial plexus (C5-T1) i.e. median nerve, radial nerve, ulnar nerve and musculocutaneous nerve. Sensory onset was considered when there was a dull sensation to pin prick along the distribution of any of these nerves (Grade 1). Complete sensory block was considered when there was complete loss of sensation to pin prick. Sensory block was graded as- Grade 0 Sharp pin felt Grade 1 Analgesia, dull sensation felt Grade 2 Anesthesia, no sensation felt Motor blockade was evaluated by the ability to flex the elbow and hand against gravity as follows : Grade 1 Ability to flex and extend the forearm Grade 2 Ability to flex or extend only the wrist and fingers Grade 3 Ability to flex or extend only the fingers Grade 4 Inability to move the forearm, wrist, and fingers Onset of motor block was defined as the time from injection of local anesthetic mixture until achieving a reduction in motor power to grade 3 or less. The block was considered incomplete when any of the segments supplied by median, radial, ulnar and musculocutaneous nerve did not have analgesia even after 30 min of drug injection. These patients were supplemented with intravenous fentanyl (2 μg/ kg) and midazolam (0.03 mg/kg). When more than one nerve remained unaffected, it was considered a failed block. In this case, general anesthesia was given intraoperatively. Patients were monitored for hemodynamic variables such as heart rate, blood pressure and oxygen saturation.

Interventions

DRUGRopivacaine

Ropivacaine 0.5% 30 ml was used to block brachial plexus

Dexmedetomidine 1 microgram per kilogram bodyweight was added with 30 ml 0.5% Ropivacaine to block brachial plexus

Sponsors

Government Medical College, Haldwani
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* 80 ASA Grade I and II patients of either sex, aged 18-60 years, undergoing various orthopaedic surgeries on the upper limb under supraclavicular brachial plexus block.

Exclusion criteria

* Patient refusal * Patients with chronic pain (pain lasting more than 12 weeks) * Those using chronic analgesic medications (opioid, non steroidal anti-inflammatory drugs, anticonvulsants, antidepressants) * Coagulopathy * History of brachial plexus injury * Allergy to the study drugs * Patients taking other medications with α-adrenergic blocking effect * Hepatic or renal insufficiency * Systemic infection or infection at the site of injection, and shoulder surgery.

Design outcomes

Primary

MeasureTime frame
Duration of Analgesiaupto 8 hours

Secondary

MeasureTime frame
Onset of Sensory Block20 minutes
Onset of Motor Block30minutes
Duration of Motor Block6 hours

Other

MeasureTime frame
Haemodynamic Changes8 hours
Complications2 hours

Participant flow

Participants by arm

ArmCount
Ropivacaine
amide local anesthetic Ropivacaine: Ropivacaine 0.5% 30 ml was used to block brachial plexus
40
Ropivacaine With Dexmedetomidine
combination of amide local anaesthetic and alpha2 agonist Ropivacaine with Dexmedetomidine: Dexmedetomidine 1 microgram per kilogram bodyweight was added with 30 ml 0.5% Ropivacaine to block brachial plexus
40
Total80

Baseline characteristics

CharacteristicRopivacaineRopivacaine With DexmedetomidineTotal
Age, Continuous35.2 years
STANDARD_DEVIATION 9.6
34.52 years
STANDARD_DEVIATION 12.8
34.86 years
STANDARD_DEVIATION 11.2
Region of Enrollment
India
40 participants40 participants80 participants
Sex: Female, Male
Female
20 Participants23 Participants43 Participants
Sex: Female, Male
Male
20 Participants17 Participants37 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 404 / 40
serious
Total, serious adverse events
0 / 400 / 40

Outcome results

Primary

Duration of Analgesia

Time frame: upto 8 hours

ArmMeasureValue (MEAN)Dispersion
RopivacaineDuration of Analgesia413.73 minutesStandard Deviation 89.92
Ropivacaine With DexmedetomidineDuration of Analgesia197.35 minutesStandard Deviation 28.67
Secondary

Duration of Motor Block

Time frame: 6 hours

Secondary

Onset of Motor Block

Time frame: 30minutes

Secondary

Onset of Sensory Block

Time frame: 20 minutes

Other Pre-specified

Complications

Time frame: 2 hours

Other Pre-specified

Haemodynamic Changes

Time frame: 8 hours

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026